SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 291 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 1.77 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,350 | -22.1% | 87,854 | -0.7% | 0.01% | -16.7% |
| Q1 2024 | $3,017 | +17.9% | 88,454 | 0.0% | 0.01% | 0.0% |
| Q4 2023 | $2,560 | +5.0% | 88,454 | 0.0% | 0.01% | 0.0% |
| Q3 2023 | $2,439 | -8.8% | 88,454 | -0.6% | 0.01% | 0.0% |
| Q2 2023 | $2,674 | -17.4% | 88,954 | -0.5% | 0.01% | -25.0% |
| Q1 2023 | $3,239 | +0.4% | 89,407 | -1.1% | 0.01% | 0.0% |
| Q4 2022 | $3,225 | -99.9% | 90,407 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $3,060,000 | +17.0% | 90,407 | 0.0% | 0.01% | +33.3% |
| Q2 2022 | $2,615,000 | -10.6% | 90,407 | -0.1% | 0.01% | 0.0% |
| Q1 2022 | $2,925,000 | +11.0% | 90,507 | +0.1% | 0.01% | +20.0% |
| Q4 2021 | $2,636,000 | +9.6% | 90,407 | +0.2% | 0.01% | 0.0% |
| Q3 2021 | $2,406,000 | -18.6% | 90,207 | -6.0% | 0.01% | -16.7% |
| Q2 2021 | $2,955,000 | +17.6% | 95,973 | 0.0% | 0.01% | +20.0% |
| Q1 2021 | $2,513,000 | +0.1% | 95,973 | -3.8% | 0.01% | 0.0% |
| Q4 2020 | $2,510,000 | +20.6% | 99,754 | -0.1% | 0.01% | 0.0% |
| Q3 2020 | $2,081,000 | -14.2% | 99,854 | -2.2% | 0.01% | -16.7% |
| Q2 2020 | $2,424,000 | +32.0% | 102,054 | 0.0% | 0.01% | 0.0% |
| Q1 2020 | $1,836,000 | -24.4% | 102,054 | -0.3% | 0.01% | 0.0% |
| Q4 2019 | $2,428,000 | +15.7% | 102,354 | +34.0% | 0.01% | +20.0% |
| Q3 2019 | $2,098,000 | -17.0% | 76,362 | 0.0% | 0.01% | -16.7% |
| Q2 2019 | $2,527,000 | -5.4% | 76,362 | +0.1% | 0.01% | -14.3% |
| Q1 2019 | $2,672,000 | +5.5% | 76,262 | 0.0% | 0.01% | 0.0% |
| Q4 2018 | $2,533,000 | -34.0% | 76,262 | 0.0% | 0.01% | -22.2% |
| Q3 2018 | $3,840,000 | -15.9% | 76,262 | 0.0% | 0.01% | -18.2% |
| Q2 2018 | $4,564,000 | +31.4% | 76,262 | +0.5% | 0.01% | +37.5% |
| Q1 2018 | $3,474,000 | +15.1% | 75,854 | +0.1% | 0.01% | +14.3% |
| Q4 2017 | $3,019,000 | +5.4% | 75,754 | +5.7% | 0.01% | 0.0% |
| Q3 2017 | $2,865,000 | -15.7% | 71,635 | -9.1% | 0.01% | -22.2% |
| Q2 2017 | $3,398,000 | +40.8% | 78,835 | +2.2% | 0.01% | +50.0% |
| Q1 2017 | $2,414,000 | +24.1% | 77,135 | +0.1% | 0.01% | +20.0% |
| Q4 2016 | $1,945,000 | +2.6% | 77,035 | +0.5% | 0.01% | 0.0% |
| Q3 2016 | $1,895,000 | +34.8% | 76,635 | +11.0% | 0.01% | +25.0% |
| Q2 2016 | $1,406,000 | +46.5% | 69,020 | +9.7% | 0.00% | +33.3% |
| Q1 2016 | $960,000 | +13.3% | 62,920 | -0.2% | 0.00% | +50.0% |
| Q4 2015 | $847,000 | +64.8% | 63,020 | +72.1% | 0.00% | +100.0% |
| Q3 2015 | $514,000 | -9.3% | 36,620 | +9.7% | 0.00% | 0.0% |
| Q2 2015 | $567,000 | – | 33,394 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $17,478,000 | 3.94% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,124,405 | $36,341,000 | 3.91% |
| ARMISTICE CAPITAL, LLC | 3,100,000 | $100,192,000 | 1.94% |
| S&T BANK/PA | 316,326 | $10,224,000 | 1.54% |
| Bruce & Co., Inc. | 222,105 | $7,178,000 | 1.47% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 379,875 | $12,278,000 | 1.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 854,949 | $27,632,000 | 1.10% |
| Soleus Capital Management, L.P. | 251,000 | $8,112,000 | 1.05% |
| Parkman Healthcare Partners LLC | 108,954 | $3,521,000 | 1.03% |
| Aristotle Capital Boston, LLC | 1,258,067 | $40,661,000 | 1.03% |